The Swiss company, which develops, manufactures, and distributes innovative medicines, has been a major player in Hungarian clinical research for decades and one of the country's largest investors.
The decision for Hungary to take the lead in clinical research in dozens of countries around the world was based on the achievements of recent years and the committed support of the Hungarian government, represented by Minister of Foreign Affairs and Trade Péter Szijjártó at the launch event in Budapest, the company noted.
Szijjártó said around 10,000 Hungarians had participated in Novartis trials in the past 10 years.
"Innovation is key to building sustainable healthcare systems in Europe. With this in mind, it is a particularly exciting opportunity for us to place greater emphasis on clinical trials in Hungary as part of our efforts to improve patient access to advanced therapies. This investment has been made possible by the Hungarian government's ambition to make the country a leader in innovation in Europe. We look forward to continuing our partnership with Hungary and working with the country's top researchers," said Haseeb Ahmad, president of Novartis Europe, at the press conference.
The company is involved in around 100 clinical research programs each year, involving more than 1,000 domestic patients each year.



